Clinical Trial Update: Bioequivalence Study of Rivaroxaban [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence study of rivaroxaban conducted by Bayer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Venous Thromboembolism

Drugs mentioned

• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: Bayer | Conditions: Embolism, Atrial Fibrillation and Venous Thrombosis | Phase 1 | Status: COMPLETED